共 27 条
[1]
Baseman J.G., Koutsky L.A., The epidemiology of human papillomavirus infections, J Clin Virol, 32, SUPPL. 1, (2005)
[2]
Keam S.J., Harper D.M., Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix], Drugs, 68, pp. 359-372, (2008)
[3]
Munoz N., Manalastas R., Pitisuttithum P., Et al., Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial, Lancet, 373, pp. 1949-1957, (2009)
[4]
Dunne E.F., Unger E.R., Sternberg M., Prevalence of HPV infection among females in the United States, JAMA, 297, pp. 813-819, (2007)
[5]
Giuliano A.R., Tortolero-Luna G., Ferrer E., Et al., Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions, Vaccine, 26, SUPPL. 10, (2008)
[6]
Burchell A.N., Winer R.L., de Sanjose S., Franco E.L., Epidemiology and transmission dynamics of genital HPV infection, Vaccine, 24, SUPPL. 3, (2006)
[7]
Moscicki A., Schiffmanb M., Kjaer S., Villa L.L., Updating the natural history of HPV and anogenital cancer, Vaccine, 24, SUPPL. 3, (2006)
[8]
Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008, Int J Cancer, 127, pp. 2893-2917, (2010)
[9]
Clifford G., Franceschi S., Diaz M., Munoz N., Villa L.L., HPV type-distribution in women with and without cervical neoplastic diseases, Vaccine, 24, SUPPL. 3, (2006)
[10]
Lacey C.J., Therapy for genital human papillomavirus-related disease, J Clin Virol, 32, SUPPL. 1, (2005)